MOR MorphoSys AG

26.04
+0.51  (+2%)
Previous Close 25.53
Open 25.94
Price To Book 6.26
Market Cap 3,287,137,110
Shares 126,234,144
Volume 22,932
Short Ratio
Av. Daily Volume 96,749

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 ContRAst trial initiation announced July 3, 2019.
Otilimab (MOR103/GSK3196165)
Rheumatoid Arthritis
Phase 2 trial to be completed 2019/20
MOR106 IGUANA
Atopic dermatitis
Phase 3 dosing has commenced - noted April 30, 2019.
TJ202/MOR202
Multiple Myeloma (MM) - second line
Phase 2 data to be presented late-2019.
MOR208 + idelalisib (COSMOS)
Chronic Lymphocytic Leukemia
Phase 3 interim analysis 2H 2019.
Bendamustine + MOR208 - B-MIND
Relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL)
Phase 2 primary endpoint met with data presented at ICML, June 22, 2019. ORR 60%, 43%. BLA filing due by end of 2019.
Lenalidomide + MOR208 - L-MIND
Relapsed or refractory diffuse large B cell lymphoma
Phase 3 enrollment has commenced - noted June 14, 2018.
Gantenerumab
Early Alzheimer's disease
Phase 2/3 trial initiation announced July 11, 2018.
Guselkumab (GALAXI 1)
Crohn's disease
Phase 2 trial initiation announced November 19, 2018.
Guselkumab (NOVA)
Hidradenitis Suppurativa
Phase 3 primary endpoint met - December 12, 2018.
Guselkumab vs Cosentyx - ECLIPSE
Psoriasis
Phase 2a initiation announced January 17, 2019.
Guselkumab
Ulcerative colitis
Approval announced February 27, 2019.
Guselkumab
Plaque psoriasis
Phase 1b trial to be initiated 2H 2019.
MOR208
Front-line diffuse large B cell lymphoma (DLBCL)
Phase 2 initiation announced April 23, 2019.
MOR106 GECKO
Atopic dermatitis

Latest News

  1. MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology
  2. Ad hoc: MorphoSys Increases Financial Guidance for 2019 Following a Milestone Payment for Antibody Otilimab (MOR103/GSK3196165) by GSK
  3. MorphoSys's Licensing Partner GSK Initiates Phase 3 Clinical Program With Otilimab (MOR103/GSK3196165) in Rheumatoid Arthritis; MorphoSys Updates its Financial Guidance for 2019
  4. CORRECTION: Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
  5. UPDATE 2-European shares fall as Daimler weighs, Sino-U.S. trade news awaited
  6. MorphoSys AG (MOR) Q1 2019 Earnings Call Transcript
  7. MorphoSys AG to Host Earnings Call
  8. MorphoSys AG Reports First Quarter 2019 Results
  9. MorphoSys and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical Study of MOR202/TJ202 in Multiple Myeloma
  10. Here’s What Hedge Funds Think About MorphoSys AG (MOR)
  11. MorphoSys and Galapagos Announce Initiation of GECKO Phase 2 Study with MOR106 in Atopic Dermatitis Patients
  12. The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives
  13. MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Familial Adenomatous Polyposis
  14. Dr. Sarah Fakih joins MorphoSys as Head of Corporate Communications and Investor Relations
  15. MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma
  16. MorphoSys Presents Results for Fiscal Year 2018
  17. MorphoSys Provides Updates on L-MIND and B-MIND Clinical Trials of MOR208 in Relapsed/Refractory DLBCL
  18. Invitation to Year-End Results 2018 Conference Call of MorphoSys AG on March 14, 2019
  19. MorphoSys to Present at Upcoming Investor Conference